Technologies to Advance the Treatment of Alzheimer's Disease
neuroscienceCME WebcastPremiere Date: Tuesday, July 23, 2013
This activity offers CE credit for:%>
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, July 23, 2014
Note: Credit Is No Longer Available
|Gary W. Small, MD
Professor of Psychiatry & Biobehavioral Sciences
Parlow-Solomon Professor on Aging
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA
|John W. Daly, MD
Clincal Professor of Medicine
Medical Director, Senior Behavioral Health
Division of Geriatrics
University of California, San Diego School of Medicine
San Diego, CA
|Val J. Lowe, MD, FACS
Professor of Radiology
Department of Radiology
Mayo Clinic School of Medicine
A clear shift in progress regarding the approach to diagnosing and managing Alzheimer's disease (AD) has been brought about by advances in the technology of biomarkers to support identification of the earliest stages of the disease. Further, a new diagnostic nomenclature now describes the various dimensions of AD in the context of biomarker findings.(1)
Education is needed for clinicians to become well informed about—and capable of using—these new technologies, as well as to use the new diagnostic approach and guide their patients into a well-informed, long-term plan.(2)
For psychiatrists who care for older patients, the premiere medical specialty meeting is the annual meeting of the American Association for Geriatric Psychiatry (AAGP). For clinicians who were unable to attend the meeting or those who did attend and want to reinforce their learning, this enduring webcast from the live symposium features expert faculty discussing the new approach to diagnosing AD, the advancing technologies, and doctor-patient conversations that support the next generation of care for dementia.
- Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9(11):1118-1127. PMID: 20934914.
- Teipel SJ, Sabri O, Grothe M, et al. Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer's disease. J Alzheimers Dis. 2013;33(0):S329-S347. PMID: 22735677.
Please register in advance for this live Q & A session because we will be sending reminder e-mails and information prior to the event. Do not miss this opportunity to exchange your thoughts and questions with Dr. Small! Click Here to Register
The goal of this educational intervention is to educate clinicians about the latest biomarker technologies for Alzheimer’s disease (AD), the new diagnostic language to support and describe the spectrum of AD, and the need to discuss the effects of an AD diagnosis with patients and families.
At the end of this CE activity, participants should be able to:
- Implement the latest biomarker technologies, such as brain imaging and cerebrospinal fluid analysis, when appropriate, in the management of patients with Alzheimer’s disease.
- Incorporate the new Alzheimer’s disease diagnostic criteria, when appropriate, into clinical practice.
- Enumerate three discussion points that can guide a discussion of the implications of Alzheimer’s disease with patients and families.
Provided by the American Association for Geriatric Psychiatry. This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Physicians and other health care professionals who work with older adults.
CME Credit (Physicians):
The American Association for Geriatric Psychiatry (AAGP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Association for Geriatric Psychiatry (AAGP) designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policy on privacy and confidentiality: Click here to view AAGP’s privacy and confidentiality policy.
Copyright: The American Association for Geriatric Psychiatry owns the copyright for this material or has obtained permission to distribute this material from all speakers.
Disclosure of Relevant Financial Relationships with Commercial Interests
American Association for Geriatric Psychiatry (AAGP) and CME Outfitters, LLC, adhere to the ACCME Standards regarding commercial support of continuing medical education. It is the policy of AAGP and CME Outfitters, LLC, that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.
A conflict of interest is created when individuals in a position to control the content of CME have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
AAGP and CME Outfitters will identify, review, and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Relevant financial relationships exist between the following individuals and commercial interests:
Dr. Small has disclosed that he serves as a consultant to Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.. He serves on the speaker's bureau of Novartis Pharmaceuticals Corporation.
Dr. Daly has no disclosures to report.
Dr. Lowe has disclosed that he has received research support from Avid Radiopharmaceuticals; GE Healthcare; and Siemans Molecular Imaging. He serves as a consultant to Bayer Pharmaceuticals and GE Healthcare.
Christine M. deVries (AAGP staff - planning committee) has nothing to disclose
Marjorie Vanderbilt (AAGP staff - planning committee) has nothing to disclose
Daniel Bateman, MD (content/peer reviewer) has nothing to disclose.
David Beck, MD (content/peer reviewer) has nothing to disclose.
Tatyana P. Shteinlukht, MD, PhD (content/peer reviewer) has nothing to disclose.
Robert Kennedy (planning committee) has nothing to disclose.
Joy Bartnett Leffler, MLA, NASW, CSE (planning committee) has nothing to disclose.
Sandra Haas Binford, MAEd (planning committee) has nothing to disclose.
Sharon Tordoff, CCMEP (planning committee) has nothing to disclose.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
AAGP, CME Outfitters, LLC, the faculty, and Lilly USA, LLC do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).